Litcius/Paper detail

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

Xiaofei Zhu, Yangsen Cao, Wenyu Liu, Xiaoping Ju, Xianzhi Zhao, Lingong Jiang, Yusheng Ye, Gang Jin, Huojun Zhang

2022The Lancet Oncology70 citationsDOI

Topics & Concepts

MedicinePembrolizumabGemcitabineTrametinibRadiation therapyOncologyRadiologyPancreatic cancerInternal medicineDeoxycytidinePhases of clinical researchClinical trialRadiosurgeryRadiomicsSurgical resectionChemoradiotherapyPancreatic neuroendocrine tumorImage-guided radiation therapySurgeryImmunotherapyExternal beam radiotherapyClinical endpointPancreatic and Hepatic Oncology ResearchCancer Immunotherapy and BiomarkersCancer Research and Treatments
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial | Litcius